| Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Tafasitamab | Phase 2 | Not yet recruiting | Sun Yat-sen University | 2026-11-16 |
| Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma | Axicabtagene ciloleucel | Phase 1 / Phase 2 | Not yet recruiting | University of Michigan Rogel Cancer Center | 2026-11-12 |
| Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALL | Blinatumomab | Not applicable | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 2026-11-06 |
| A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) | Tafasitamab | Phase 2 / Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 2026-11-05 |
| Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Blinatumomab | Phase 1 | Not yet recruiting | City of Hope Medical Center | 2026-11-03 |
| Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK_D332) in Combination With Tafasitamab and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Tafasitamab | Phase 1 | Not yet recruiting | Istituto Oncologico Veneto IRCCS | 2026-10-30 |
| Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy | Axicabtagene ciloleucel, Brexucabtagene autoleucel | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 2026-10-23 |
| BLinatumomab and iNKT in Relapsed B-Cell ALL | Blinatumomab | Phase 1 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 2026-10-09 |
| Inebilizumab for the Treatment of Patients With Type 1 Autoimmune Pancreatitis | Inebilizumab | Phase 4 | Recruiting | Ruijin Hospital | 2026-10-07 |
| Exploratory Study on the Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Severe Primary Sjögren's Syndrome | Blinatumomab | Phase 2 | Not yet recruiting | Beijing Tongren Hospital | 2026-10-01 |
| A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy | Inebilizumab | Phase 3 | Recruiting | Amgen | 2026-10-01 |
| Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL | Blinatumomab | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 2026-09-25 |
| Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma | Lisocabtagene maraleucel | — | Active, not recruiting | Bristol-Myers Squibb | 2026-08-20 |
| Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma | Axicabtagene ciloleucel, Brexucabtagene autoleucel | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 2026-08-13 |
| Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma | Tafasitamab | Phase 2 | Recruiting | University of Washington | 2026-07-28 |
| CD19-B Cell Depletion in PAIS-ME/CFS Patients | Inebilizumab | Phase 2 | Not yet recruiting | Charite University, Berlin, Germany | 2026-07-24 |
| Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma | Axicabtagene ciloleucel, Lisocabtagene maraleucel | Phase 1 | Recruiting | Weill Medical College of Cornell University | 2026-07-24 |
| A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL | Blinatumomab | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 2026-07-23 |
| GLORY: Glofit-GemOx With Liso-Cel For Lymphoma | Lisocabtagene maraleucel | Phase 2 | Recruiting | Massachusetts General Hospital | 2026-07-17 |
| Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study | Tafasitamab | — | Active, not recruiting | TTY Biopharm | 2026-07-16 |
| Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) as Conditioning Regimen for ABO-incompatible Living Donor Kidney Transplantation | Blinatumomab | Early phase 1 | Not yet recruiting | West China Hospital | 2026-07-15 |
| Safety and Efficacy of BiTE in Desensitization Therapy for Highly Sensitized Kidney Transplant Candidates With cPRA ≥ 90% | Blinatumomab | Phase 4 | Not yet recruiting | West China Hospital | 2026-07-08 |
| Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma | Tisagenlecleucel | Phase 1 | Recruiting | Nathan Denlinger | 2026-06-30 |
| Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma | Brexucabtagene autoleucel | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 2026-06-29 |
| Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Transplantation Combined With Tafasitamab, Lenalidomide, and Standard Immunochemotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma | Tafasitamab | Phase 2 | Active, not recruiting | The First Affiliated Hospital of Soochow University | 2026-06-02 |
| A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma. | Axicabtagene ciloleucel | Early phase 1 | Recruiting | Shenzhen Fosun Kairos Biotechnology Co., Ltd. | 2026-05-26 |
| A Trial of Inebilizumab in Participants With Autoimmune Hepatitis | Inebilizumab | Phase 3 | Recruiting | Amgen | 2026-05-20 |
| A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide | Tafasitamab | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 2026-05-14 |
| Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Tafasitamab | Phase 2 | Recruiting | City of Hope Medical Center | 2026-05-12 |
| Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO) | Loncastuximab tesirine | Phase 1 / Phase 2 | Recruiting | University of Utah | 2026-05-07 |
| CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors. | Axicabtagene ciloleucel | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 2026-04-20 |
| Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy | Axicabtagene ciloleucel | Phase 3 | Active, not recruiting | Kite, A Gilead Company | 2026-03-18 |
| A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia | Obecabtagene autoleucel | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 2026-02-10 |
| A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy | Tisagenlecleucel | — | Recruiting | Novartis Pharmaceuticals | 2026-01-30 |
| Glofitamab Combined With CAR-T Therapy in R/R DLBCL | Axicabtagene ciloleucel | Phase 2 | Not yet recruiting | Ruijin Hospital | 2026-01-08 |
| Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma | Lisocabtagene maraleucel | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 2026-01-05 |
| A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies | Loncastuximab tesirine | Phase 1 | Recruiting | Janssen Research & Development, LLC | 2025-12-29 |
| Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD | Inebilizumab | Phase 2 | Recruiting | Amgen | 2025-10-30 |
| Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Loncastuximab tesirine | Phase 2 | Recruiting | Universität Münster | 2025-09-29 |
| Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Lisocabtagene maraleucel | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 2025-09-26 |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | Lisocabtagene maraleucel | Phase 3 | Recruiting | Lyell Immunopharma, Inc. | 2025-09-23 |
| Inectolizumab With Steroid Optimization in Newly Treated NMOSD | Inebilizumab | Not applicable | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 2025-09-08 |
| Obe-cel in Refractory Progressive Forms of Multiple Sclerosis | Obecabtagene autoleucel | Phase 1 | Recruiting | Autolus Limited | 2025-08-24 |
| Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD | Inebilizumab | Phase 3 | Not yet recruiting | Tianjin Medical University General Hospital | 2025-08-20 |
| Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN) | Obecabtagene autoleucel | Phase 2 | Recruiting | Autolus Limited | 2025-07-08 |
| Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL) | Obecabtagene autoleucel | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 2025-07-08 |
| NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma | Lisocabtagene maraleucel | Phase 1 | Recruiting | Washington University School of Medicine | 2025-07-04 |
| A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma | Lisocabtagene maraleucel | Phase 2 | Recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2025-06-11 |
| Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD | Inebilizumab | Phase 4 | Recruiting | Massachusetts General Hospital | 2025-06-08 |
| Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL) | Loncastuximab tesirine | Phase 1 | Recruiting | The University of Texas Health Science Center at San Antonio | 2025-05-18 |
| Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure | Loncastuximab tesirine | Phase 2 | Recruiting | Istituto Clinico Humanitas | 2025-04-09 |
| Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma | Loncastuximab tesirine | Phase 2 | Recruiting | University of Miami | 2025-04-09 |
| Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL) | Loncastuximab tesirine | Phase 2 | Recruiting | University of Utah | 2025-01-23 |
| Long-term Follow up Local Registry Study of Kymriah in South Korea | Tisagenlecleucel | — | Recruiting | Novartis Pharmaceuticals | 2025-01-21 |
| Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR) | Loncastuximab tesirine | Phase 1 | Recruiting | University of Utah | 2024-09-23 |
| A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) | Obexelimab | Phase 2 | Active, not recruiting | Zenas BioPharma (USA), LLC | 2024-08-21 |
| A Study of Obexelimab in Patients With Systemic Lupus Erythematosus | Obexelimab | Phase 2 | Active, not recruiting | Zenas BioPharma (USA), LLC | 2024-08-19 |
| Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL | Brexucabtagene autoleucel | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 2024-08-14 |
| CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma | Brexucabtagene autoleucel | Phase 2 | Recruiting | Christian Schmidt, MD | 2024-07-01 |
| Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies | Tisagenlecleucel | Phase 1 | Recruiting | Stanford University | 2024-05-10 |
| Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus | Obecabtagene autoleucel | Phase 1 | Active, not recruiting | Autolus Limited | 2024-03-27 |
| Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab | Brexucabtagene autoleucel | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 2024-03-01 |
| Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Brexucabtagene autoleucel | Phase 2 | Active, not recruiting | Kite, A Gilead Company | 2024-02-12 |
| A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma | Brexucabtagene autoleucel | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 2024-01-19 |
| A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) | Obecabtagene autoleucel | Phase 1 | Recruiting | Autolus Limited | 2023-12-15 |
| A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma | Tisagenlecleucel | Phase 3 | Active, not recruiting | Novartis Pharmaceuticals | 2023-06-05 |
| Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy | Tisagenlecleucel | — | Recruiting | Stanford University | 2023-05-18 |
| A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre) | Obexelimab | Phase 3 | Active, not recruiting | Zenas BioPharma (USA), LLC | 2023-03-27 |
| A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease | Obexelimab | Phase 3 | Active, not recruiting | Zenas BioPharma (USA), LLC | 2022-12-22 |
| Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Tisagenlecleucel | Phase 2 | Recruiting | SWOG Cancer Research Network | 2022-12-01 |
| Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies | Tisagenlecleucel | — | Recruiting | Novartis Pharmaceuticals | 2022-09-15 |
| A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) | Obecabtagene autoleucel | Phase 1 / Phase 2 | Active, not recruiting | Autolus Limited | 2020-05-27 |